Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 8
- Registration Number
- NCT00864032
- Locations
- 🇺🇸
University of california, Davis Medical Center, Sacramento, California, United States
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
- Conditions
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 88
- Registration Number
- NCT00861419
First Line Hepato Cellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1714
- Registration Number
- NCT00858871
- Locations
- 🇺🇸
Agajanian Institute Of Hematology And Oncology, Downey, California, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸James Graham Brown Cancer Center, Louisville, Kentucky, United States
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 9
- Registration Number
- NCT00854620
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- Egyptian Foundation For Cancer Research
- Target Recruit Count
- 75
- Registration Number
- NCT00848640
- Locations
- 🇪🇬
Egyptian Foundation For Cancer Research, Cairo, Egypt
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 24
- Registration Number
- NCT00846131
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2009-02-16
- Lead Sponsor
- Combined Military Hospital, Pakistan
- Target Recruit Count
- 30
- Registration Number
- NCT00844688
- Locations
- 🇵🇰
Combined Military Hospital, Rawalpindi, Punjab, Pakistan
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT00844883
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 43
- Registration Number
- NCT00839111
- Locations
- 🇨🇳
Cancer Hospital,Fudan University, Shanghai, Shanghai, China
Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00837876
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸Purchase Cancer Group - Paducah, Paducah, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.